Abstract
mAb that recognise various cell surface receptors have been used to deliver antigen to DC and thereby elicit immune responses. The encouraging data obtained in mouse models suggests that this immunisation strategy is efficient and could lead to clinical trials. We discuss a number of issues pertinent to this vaccination approach. These include which molecules are the best targets for delivering antigen to DC, which DC subtypes should be targeted, the types of immune responses to be generated and whether additional adjuvants are required. Finally, we discuss some progress towards targeting antigen to human DC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antigen Presentation / immunology*
-
Dendritic Cells / immunology*
-
Dendritic Cells / metabolism
-
Humans
-
Immune Tolerance / immunology
-
Interferon-gamma / immunology
-
Interferon-gamma / metabolism
-
Lectins, C-Type / immunology*
-
Lectins, C-Type / metabolism
-
Membrane Proteins / immunology*
-
Membrane Proteins / metabolism
-
Mice
-
Nerve Tissue Proteins / immunology*
-
Nerve Tissue Proteins / metabolism
-
Receptors, Immunologic / immunology*
-
Receptors, Immunologic / metabolism
-
Receptors, Mitogen / immunology*
-
Receptors, Mitogen / metabolism
-
T-Lymphocyte Subsets / immunology*
-
T-Lymphocyte Subsets / metabolism
Substances
-
Adjuvants, Immunologic
-
Antibodies, Monoclonal
-
CLEC9a protein, human
-
Clec9a protein, mouse
-
Lectins, C-Type
-
Membrane Proteins
-
Nerve Tissue Proteins
-
Receptors, Immunologic
-
Receptors, Mitogen
-
dectin 1
-
Interferon-gamma